Advanced search
Publication Cover
Current Medical Research and Opinion Volume 38, 2022 - Issue 7
Submit an article Journal homepage
2,763
Views
5
CrossRef citations to date
0
Altmetric
Neurology

The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets

Helmut Butzkuevena Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia;b The Alfred Hospital, Melbourne, AustraliaCorrespondence[email protected]
,
Nicholas Moorec Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France
,
Aida Aydemird Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA)
,
Jaak Sõnajalge Global Database Studies, IQVIA, Tartu, Estonia
,
Irene Bezemerf Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands
,
Pasi Korhoneng IQVIA (former EPID Research), Espoo, Finland
,
Meritxell Sabidóh Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany
& on behalf of the CLARION Study Group show all
Pages 1167-1176 | Received 07 Jan 2022, Accepted 28 Mar 2022, Published online: 28 Apr 2022

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó. (2023) The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis. Current Medical Research and Opinion 39:10, pages 1367-1374.
Read now

Articles from other publishers (4)

Ardra Shephard, Laura Kolaczkowski, Noreen Barker, Donna Nahal, Celia Oreja-Guevara, Saúl Reyes, Helen Gray, Hashem Salloukh & Gavin Giovannoni. (2024) Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals. Neurology and Therapy.
Crossref
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Ali-Frederic Ben-Amor, Carine Savarin & Gilles Defer. (2023) Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis. Neurology and Therapy 12:5, pages 1457-1476.
Crossref
Wallace J. Brownlee, Aiden Haghikia, Brooke Hayward, Nathalie Waser, Sheena Kayaniyil, Zaeem Khan, Julie Duncan, Stefanie Millar & Gerard T. Harty. (2023) Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study. Multiple Sclerosis and Related Disorders 76, pages 104791.
Crossref
Kazuo Nakamichi, Yoshiharu Miura, Toshio Shimokawa, Kenta Takahashi, Tadaki Suzuki, Nobuaki Funata, Masafumi Harada, Koichiro Mori, Nobuo Sanjo, Motohiro Yukitake, Kazuya Takahashi, Tsuyoshi Hamaguchi, Shoko Izaki, Satoru Oji, Jin Nakahara, Ryusuke Ae, Koki Kosami, Souichi Nukuzuma, Yosikazu Nakamura, Kyoichi Nomura, Shuji Kishida, Hidehiro Mizusawa, Masahito Yamada, Masaki Takao, Hideki Ebihara & Masayuki Saijo. (2023) Nationwide Laboratory Surveillance of Progressive Multifocal Leukoencephalopathy in Japan: Fiscal Years 2011–2020. Viruses 15:4, pages 968.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.